Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Vol.27, 2026.8.26
Celebrating milestone moments with Qiming Venture Partners' portfolio companies.
Editor's Note: In 2026, the Qiming Weekly gets a fresh upgrade, with regular weekly updates featuring only ten major developments from Qiming Venture Partners' portfolio companies, covering funding progress and breakthrough achievements.
Every step entrepreneurs take in the wave of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and join you in tracking the milestone moments of its portfolio companies.
Major Partnerships
01/ Shengshu Technology's Vidu S1 Powers 360's New Digital Human Experience for Empresses in the Palace
Recently, Qiming Venture Partners portfolio company Shengshu Technology's Vidu entered into a deep technical partnership with 360. Leveraging its self-developed Vidu S1 real-time interactive video generation model as the underlying infrastructure, it powered the "Empresses in the Palace 360 Fan Meetup" online H5 campaign. Relying on real-time interactive digital human technology, it reconstructed the bidirectional emotional connection between classic IP and fans, exploring a new lightweight entertainment digital human marketing approach.
This implementation went beyond demonstration-style demos to complete real-world validation with public domain users. It marks an important practice for Vidu's real-time interactive video model in the mass entertainment marketing track, validating that lightweight H5 digital humans can handle massive concurrent traffic from public domains, delivering replicable and scalable AI interaction solutions for film/TV IP and brand marketing.
02/ Insilico Medicine Partners with Byterna Therapeutics on Next-Generation mRNA Cancer Vaccines
Recently, Qiming Venture Partners portfolio company Insilico Medicine (03696.HK), a generative AI-driven clinical-stage biotech firm, announced a formal R&D collaboration with Byterna Therapeutics, a company focused on next-generation RNA innovative drug development. The two parties will jointly build a next-generation mRNA AI-native R&D engine around AI neoantigen prediction and sequence design, circular mRNA, targeted delivery, automated experimentation, and intelligent manufacturing, exploring individualized tumor vaccines and related innovative therapies.
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, stated: "The pivotal clinical progress of individualized mRNA tumor vaccines has given the industry a clearer view of this track's potential. Future core competitiveness lies in forming a high-quality closed loop of neoantigen prediction, sequence engineering, delivery, automated validation, and intelligent manufacturing. We hope to combine Pharma.AI with Byterna Therapeutics' next-generation RNA platform to expand AI drug R&D into new modalities."
03/ UBTECH and Basic Semiconductor Enter Strategic Partnership
At the 2026 World Robot Conference, Qiming Venture Partners portfolio company UBTECH (09880.HK) formally signed a strategic cooperation agreement with Shenzhen Basic Semiconductor Co., Ltd. The two parties will leverage UBTECH's technical and mass production advantages in embodied intelligent humanoid robots, combined with Basic Semiconductor's core technology and industrialization capabilities in silicon carbide power devices, to conduct in-depth collaboration around humanoid robot energy efficiency optimization and low-power, high-endurance product development, accelerating the scaled application of silicon carbide power devices in embodied intelligent robots.
As the "first humanoid robot stock," UBTECH focuses on embodied intelligent robot R&D and scenario deployment, with extensive industry experience and application trend judgment capabilities. As a listed Chinese third-generation semiconductor silicon carbide power device company, Basic Semiconductor has achieved autonomous control across the full industrial chain of silicon carbide chip design, wafer manufacturing, packaging and testing, and drive application. Its core products include silicon carbide MOSFETs, automotive-grade and industrial-grade power modules, and more. Through this collaboration, the two parties will conduct research and validation on the application of silicon carbide power devices in robot power management, motion control, and other modules, jointly promoting their widespread use in embodied intelligent humanoid robots and fostering new quality productive forces.
Product Launches
01/ Zhipu AI's GLM-5.3 Goes Live
Recently, Qiming Venture Partners portfolio company Zhipu AI (02513.HK) officially launched the GLM-5.3 API. The model excels at complex coding, defensive cybersecurity, and long-horizon tasks. GLM-5.3 scored 60 points on the globally authoritative Artificial Analysis Intelligence Index (AA Composite Intelligence Index), entering the frontier model capability tier and placing it on par with closed-source flagship models such as Claude Fable 5 and GPT-5.6 Sol, while tying with Moonshot AI's K3 for first place among open-source models.
While achieving comparable intelligence levels, GLM-5.3 significantly lowers the barrier to accessing frontier model capabilities through smaller parameter scale and lower call costs. GLM-5.3 pursues not just the upper limits of intelligence, but also seeks to maximize the intelligence gained per unit cost. With the API now officially open, frontier intelligence will enter the real-world work scenarios of more developers, enterprises, and knowledge workers.
02/ Galaxy Universal Unveils GALBOT ET1, the World's First Self-Learning Intelligent Agent Humanoid Robot
Recently, Qiming Venture Partners portfolio company Galaxy Universal made a major announcement: GALBOT ET1 ("Galaxy Star"), the world's first self-learning intelligent agent humanoid robot. Compared to other humanoid robots, ET1's defining characteristic is agility — and the technical backbone behind this agility is Galaxy Universal's self-developed AstraBrain-WBC general cerebellar foundation model.
What truly makes this "general cerebellum" powerful is Galaxy Universal's globally largest-scale 100,000-hour human motion data training — with data partly from high-precision motion capture and partly from direct retargeting of internet human videos. The team has also built the "Galaxy Star Data" foundation, continuously supporting Galaxy Universal's mission to define the world's next-generation top-tier locomotion control model. It is precisely because of this that ET1's core trait emerges — genuine human-like autonomous learning capability. Without motion capture, without action videos, it can identify and extract motion trajectories through real-time interaction with humans, learning and reproducing on the spot.
03/ Noitom Robotics Releases AdaPT
During the 2026 World Robot Conference, Qiming Venture Partners portfolio company Noitom Robotics officially released AdaPT (Adaptive Motion Planning and Tracking), a humanoid robot professional tennis learning framework that enables humanoid robots to learn from professional tennis players' videos and motion capture data, translating movement styles into tennis skills that real robots can execute.
According to the simultaneously published academic paper (https://arxiv.org/abs/2608.20087), the research team extracted and learned the forehand, backhand rally, and serving styles of three professional players — Rafael Nadal, Roger Federer, and Novak Djokovic — from publicly available match videos. These movement styles were then presented on Unitree's G1 robot. Additionally, AdaPT learned a set of tennis movements from motion capture data of top domestic professional athletes. The research team migrated this methodology to the approximately 1.7-meter-tall full-size DOBOT Atom humanoid robot, and further completed deployment validation in real tennis scenarios.
04/ DeepWise Releases Bohr·Science Space
Recently, Qiming Venture Partners portfolio company DeepWise officially launched Bohr·Science Space, connecting scientific knowledge, data, models, software, computing power, and experimental resources. It features built-in AI scientists for different disciplines, supporting the complete research workflow from scientific investigation, hypothesis generation, and experimental design to computational verification, data analysis, and output of results — moving AI from merely answering questions to executing real scientific research tasks.
Meanwhile, DeepWise has launched the "Bohr 107 Initiative," soliciting questions of important scientific value and exploratory potential from researchers worldwide. Leveraging the capabilities of Bohr·Science Space and its AI scientists, selected questions will receive comprehensive research support from scientific investigation and hypothesis deduction to computational simulation and result validation, driving valuable scientific questions from formulation toward sustained exploration.
Technology Strength
01/ Hesai Technology Appears at 2026 World Robot Conference
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI, 02525.HK) appeared at the 2026 World Robot Conference in Beijing, showcasing multiple products and technological achievements for robotics and physical AI — the 6D full-color lidar supersensitive chip platform "Picasso," the world's first 6D full-color lidar ETX, the spatial intelligence platform Kosmo, and the miniaturized lidar JT128, the perception choice of leading embodied intelligence companies.
From underlying chips and perception hardware to spatial intelligence, Hesai Technology continues to refine its physical AI infrastructure layout, providing high-quality perception and data foundations for robots entering the real world and accelerating the scaled application of physical AI. At the exhibition booth, Unitree Technology's Spring Festival Gala同款 G1 Pro humanoid robot and Vbot super-capable robotic dog "Datou" equipped with Hesai Technology lidar were also on display, further demonstrating Hesai Technology's extensive applications in the robotics perception field.
02/ Yunji Technology's "Human-Machine Symbiotic World Value Model" Full Product Line Appears at 2026 World Robot Conference
Recently, Qiming Venture Partners portfolio company Yunji Technology (02670.HK) made its first public appearance with its "Human-Machine Symbiotic World Value Model" full product matrix under the exhibition theme "Making Value Real in the Physical World — Embodied Intelligence + AI + AIoT Full Scenarios." Within the exhibition area, six 24-hour full-AI scenarios — smart hotel, smart laundry, convenience GO, retail vending cabinet, latte art coffee, and fresh-cooked noodles — were laid out in concentration, covering clothing, food, housing, and transportation in daily life, sketching out a tangible and touchable intelligent living picture.
The booth centrally presented six 24-hour full-AI scenarios: smart hotel, smart laundry, convenience GO, retail vending cabinet, latte art coffee, and fresh-cooked noodles. These scenarios were not independent equipment demonstrations but an integrated full-scenario intelligent system covering accommodation, lifestyle services, retail, and dining. AI runs through the entire process from demand initiation, task comprehension to device collaborative response, giving every life scenario the ability to respond at any time.
R&D Progress
Gan & Lee Pharmaceuticals' Insulin Glargine Pre-Filled Pen Receives Thailand Marketing Approval
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that its self-developed insulin glargine injection pre-filled pen has officially received marketing approval from the Thai Food and Drug Administration, indicated for diabetes treatment. This marks another important step forward in the company's internationalization strategy and deepening presence in the Southeast Asian market. Previously, the company's insulin glargine injection and accompanying reusable pen were already marketed in Thailand. With this approval of the insulin glargine injection pre-filled pen, the company further enriches its local product portfolio in Thailand, providing Thai medical institutions and diabetic patients with more flexible and convenient basal insulin treatment options.
As a core market for chronic disease diagnosis and treatment in Southeast Asia, Thailand has a large diabetic population with clear demand for long-term standardized medication, showing significant market growth potential. According to International Diabetes Federation data from the IDF Diabetes Atlas, Thailand had 6.36 million adults aged 20–79 with diabetes in 2024, with a prevalence rate of 11.7%. The market's demand for basal insulin products with stable quality, high cost-effectiveness, and convenient administration is growing daily, creating market opportunities for the overseas expansion of high-quality domestic insulin.
Past Issues
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.